Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
BR-101801 by Boryung Pharmaceutical for Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy: Likelihood of Approval
BR-101801 is under clinical development by Boryung Pharmaceutical and currently in Phase I for Angioimmunoblastic T-Cell Lymphoma (AITL)/Immunoblastic Lymphadenopathy. According...
BR-1018 by Boryung Pharmaceutical for Hypercholesterolemia: Likelihood of Approval
BR-1018 is under clinical development by Boryung Pharmaceutical and currently in Phase III for Hypercholesterolemia. According to GlobalData, Phase III...
BR-1018 by Boryung Pharmaceutical for Idiopathic (Essential) Hypertension: Likelihood of Approval
BR-1018 is under clinical development by Boryung Pharmaceutical and currently in Phase III for Idiopathic (Essential) Hypertension. According to GlobalData,...
BR-6002 by Boryung Pharmaceutical for Duodenal Ulcer: Likelihood of Approval
BR-6002 is under clinical development by Boryung Pharmaceutical and currently in Phase I for Duodenal Ulcer. According to GlobalData, Phase...
BR-6002 by Boryung Pharmaceutical for Cardiovascular Disease: Likelihood of Approval
BR-6002 is under clinical development by Boryung Pharmaceutical and currently in Phase I for Cardiovascular Disease. According to GlobalData, Phase...
BR-6002 by Boryung Pharmaceutical for Gastric Ulcers: Likelihood of Approval
BR-6002 is under clinical development by Boryung Pharmaceutical and currently in Phase I for Gastric Ulcers. According to GlobalData, Phase...